Please assess the completion status of the following clinical trial:

Trial Title: Baclofen Effects on Smoking Urge and Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke at least 10 cigarettes per day for at least 6 months and considering quitting smoking in the next 6 months-~Exclusion Criteria:~* Planning to attempt smoking cessation within the next 4 months~* Weight less than 110 lbs. or above 220 lbs.~* Use of tobacco products other than cigarettes in the previous month.~* History of: Kidney disease, uncontrolled conditions (e.g., cardiac disease, pulmonary disease, diabetes, hypertension) Neurological disease (including stroke, mini-stroke, brain injury, Alzheimers Disease, encephalitis, meningitis, seizure disorder),Phenylketonuria Schizophrenia, Schizoaffective Disorder, Paranoid Disorder, or Schizotypal Disorder.~* Current alcohol and/or drug use disorder as indicated by a screening questionnaire, past treatment for alcohol or substance use problems unless in remission(clean and sober for past year or more) or intention to seek treatment in the next 6 months for alcohol or substance use problems.~* For women: Pregnancy, nursing, not using a reliable form of birth control.~* Allergy to baclofen, Lioresal, or Kemstro.~* Taking the following medications: antidepressants(excluding selective serotonin reuptake inhibitors), bupropion, phenothiazines, antihistamines, sedative/hypnotics, benzodiazepines, alpha blockers, beta blockers.~* Lives with someone enrolled in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Baclofen condition (Type: EXPERIMENTAL): Baclofen taken orally for 12 days total up to 40 mg/day maximum, divided into 3 equal portions each day. Participants receive 12 mg/day the first 3 days, 30 mg/day the next 3 days, and 40 mg/day on Days 7, 8, 9. Testing is on day 10 after the first dose is taken, with downward titration days 10-12 of 30 mg on Day 10, 20 mg on Day 11 and 10 mg on Day 12.
- Placebo condition (Type: PLACEBO_COMPARATOR): Placebo capsules identical to active medication, 3/day for 12 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).